BIVI Earnings — BioVie, Inc. Common Stock Post-ER Performance | BigEarnings
BIVI — BioVie, Inc. Common Stock
XNAS
Price$1.80
Market Cap$17.1M
P/E—
52W Range$1.06 – $9.09
Next Earnings2026-08-14
About BioVie, Inc. Common Stock
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
